New Study Examines cResponse Efficacy in Assessing Pancreatic Cancer Treatment Responses

Photo Credit: Curesponse

REẖOVOT, Israel, October 3, 2023 (VSNewsNetwork.com) - A recently published article in "Cancer Discovery" explored the range of responses in Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) to platinum and PARPi treatments. The study delved into the genomic and clinical aspects influencing diverse responses and inspected resistance mechanisms.

This pivotal research, titled "Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting," was spearheaded by Dr. Talia Golan of Sheba Medical Center and Chani Stossel, Ph.D., of the Oncology Institute.

In their work, the team detailed clinical outcomes of 125 glBRCA PDAC patients who were classified based on platinum/PARP inhibition response durations. They also generated patient-derived xenografts (PDX) from 25 glBRCA PDAC patients at varying clinical stages, connecting in vivo and ex vivo culture (EVOC) responses to patients' clinical reactions.

The study made use of the cResponse assay, a collaborative product from Curesponse and the Weizmann Institute of Science. This assay is currently operational in Curesponse laboratories across the UK and Israel. A significant alignment between EVOC's sensitivity to certain treatments and in vivo tumor growth was recorded.

Highlighting the assay's potential, the researchers pointed out its swift turnaround time and the feasibility of running multiple treatment combinations concurrently.

The overarching findings accentuated the favorable response of glBRCA PDAC to platinum/PARP inhibition, though resistance emerges in many patients. The study's model systems in PDXs and EVOC offer a reliable basis for researching resistance mechanisms and fueling subsequent drug development.

Dr. Vered Bar, the VP of Research & Development at Curesponse, commented, "The collaboration with Sheba's Pancreatic Cancer Center for this study was pivotal. The robust correlation between clinical patient responses and the cResponse algorithm score underscores our tool's ability to aid oncologists in tailoring optimal treatments for individual patients."

The innovative cResponse platform merges rapid next-generation sequencing (NGS) with a distinct functional assay, gauging cancerous tissue reactions to varied drugs while preserving the tumor microenvironment (TME). This fusion establishes the first personalized cancer tool that provides an empirical test, reflecting a tumor's response to treatments within a fortnight from biopsy, and is applicable across multiple therapeutic methods.

With CE marking and ISO 15189-accredited laboratory status, the cResponse test is already compensated by private payers in Israel for guiding personalized cancer treatments. By 2024, this test is expected to be available for cancer patients in the UK, EU, and the USA.

For more details, visit www.curesponse.com.

Source: Curesponse via Newswire